Sabal Trust CO increased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 4,528.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 421,946 shares of the biopharmaceutical company’s stock after buying an additional 412,830 shares during the period. Bristol-Myers Squibb accounts for 2.7% of Sabal Trust CO’s holdings, making the stock its 11th biggest holding. Sabal Trust CO’s holdings in Bristol-Myers Squibb were worth $26,895,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tradewinds Capital Management LLC grew its holdings in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the period. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb in the second quarter worth $111,000. American National Bank grew its holdings in Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 225 shares during the period. Blue Chip Partners Inc. grew its holdings in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the period. Finally, BDO Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the second quarter worth $123,000. 69.66% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.

A number of equities research analysts have commented on the stock. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Finally, Credit Suisse Group restated a “hold” rating and issued a $61.00 price target (up from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.93.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.40 on Tuesday. The stock has a market cap of $102,154.63, a PE ratio of 21.09, a PEG ratio of 2.37 and a beta of 1.18. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.

WARNING: “Sabal Trust CO Has $26.90 Million Position in Bristol-Myers Squibb Company (BMY)” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/sabal-trust-co-has-26-90-million-position-in-bristol-myers-squibb-company-bmy/1772571.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.